ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1620

Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab

Ye Liu1, Tarun Arora2, S. Bobo Tanner3 and Jeffrey Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, 3Vanderbilt University Medical Center, Nashville, TN

Meeting: ACR Convergence 2023

Keywords: Heart disease, osteoporosis, Pharmacoepidemiology, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Health Services Research II

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Romosozumab (romo) and denosumab (dmab) are recommended for postmenopausal women with osteoporosis (OP) at high risk of fracture. The U.S. prescribing information includes a boxed warning that romo should not be initiated in patients with prior myocardial infarction or stroke in the prior year. Forall other patients without recent MI or stroke, the warning recommends to consider whether the benefits of romo outweigh its risks. This study evaluated CV and fracture risks among patients who initiated romo referent to dmab users.

Methods: We used Medicare data from 1/1/2017 to 9/30/2021 to identify women age ≥55 newly initiating romo or dmab after 4/1/2019.Claims data was linked to electronic medical record (EMR) data from multiple PCORNet Clinical Research Networks. Comorbidities and medical history were identified from claims while biometric data and lipid test results were obtained from the EMR. The ACC/AHA pooled cohort risk equation was used to calculate the 10-year CV risk. The FRAX algorithm was used to calculate 10-year risk of hip and major fracture (clinical spine, forearm, hip, or shoulder). We set the 75 percentile of each risk score as the cut-off for high CV and fracture risk. A scatter plot with 95% prediction ellipse was used to illustrate the relationship between CV risk versus the risk of fractures (Figure 1) at a patient level and to compare the cohort of romo vs. dmab patients. Multivariable logistic regression was used to evaluate the relationship between high CV or fracture risk and medication initiation.

Results: A total of 197,515 new users of romo(n=14,596)or dmab (n=182,919) were eligible for analysis and 1072 were linked to PCORNet data. Figure 1 showed romo users had lower CV risk but comparable or higher risk for hip or major fracture compared with dmab users. Romo was more likely to be prescribed to patients with higher fracture risk but lower CV risk, compared with dmab. The odds ratios (95% CI) for initiating romo vs. dmab for high CV risk, hip fracture risk, and major fracture risk were 0.46 (0.26, 0.80), 0.97 (0.47, 2.01), and 1.83 (0.89, 3.75), respectively.

Conclusion: In this cohort of older women with claims data linked to EHR data, patients with high CV risk were less likely to be given romo compared with dmab. These data suggest that the boxed warning regarding CV risk for romo appropriately influences clinical decision making of physicians when prescribing anabolic medications for osteoporosis patients.

Supporting image 1


Disclosures: Y. Liu: None; T. Arora: Amgen, 5; S. Tanner: None; J. Curtis: AbbVie, 2, 5, Amgen, 2, 5, Bristol Myers Squibb, 2, 5, CorEvitas, 2, 5, Janssen, 2, 5, Lilly, 2, 5, Myriad, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Liu Y, Arora T, Tanner S, Curtis J. Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-risk-and-fracture-risk-among-women-initiating-treatment-with-romosozumab-or-denosumab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-and-fracture-risk-among-women-initiating-treatment-with-romosozumab-or-denosumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology